Fennec Pharmaceuticals Rating Reiterated After Study Expansion H.C. Wainwright reiterated coverage on Apr 8, 2026 after Fennec expanded trial enrollment from 30 to 85 patients (+183%), per company release.

Fennec Pharmaceuticals Rating Reiterated After Study Expansion: H.C. Wainwright reiterated coverage on Apr 8, 2026 after Fennec expanded trial enrollment from 30 to 85 patients (+183%), per… 👈 Read full analysis #FennecPharmaceuticals #ClinicalTrials #PharmaNews #Healthcare #ResearchExpansion